Trial Profile
Phase IA Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Toripalimab (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Gastric cancer; Head and neck cancer; Malignant melanoma; Nasopharyngeal cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai Junshi Biosciences
- 07 Mar 2019 Status changed from active, no longer recruiting to completed.
- 11 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 26 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.